GlimmerX:

Global ImmunoDiagnostics

Game-Changing Diagnostics Development for Difficult-to-Diagnose and Difficult-to-Treat Bacterial Infections

GlimmerX

GlimmerX: A holding company

Joe Vinetz, M.D.

Founder, Consultant

Professor, Yale School of Medicine

>$48 million in research funding to date; well connected in industry; Expert in assay development, animal models, microbiology, immunology and human/field testing

Carla Devillers, M.B.A.

Founding Executive

Wharton M.B.A.

Highly experienced international finance, operations, and business development executive

Tsvi Goldenberg, Ph.D

Partner

Experienced innovator in start-ups

Serial entrepreneur

Legal

WSGR

Wilson Sonsini Goodrich & Rosati:

Global intellectual property and corporate lawyers

Yale Accelerator for Innovation Development Team:

Colleen Lopez, PhD

Eva Leung

Konstantine Drakonakis

A story …


Suzy!
Kauai
Niihau
Oahu
Molokai
Lanai
Maui
Kahoolawe
The Hawaiian Islands
Hawaii
(The Big island)

The Leptospirosis problem

Leptospirosis is the Ebola virus of the bacterial world



Current technology to diagnose leptospirosis in animals and humans performs poorly… can take weeks to identify a plan of action

With a 20% mortality rate, leptospirosis can be fatal if not diagnosed and treated in a timely manner

The Solution: GlimmerX

- Patent-pending IP/technology
- BETTER, FASTER platform for point-of-care diagnosis
- QUICK, RELIABLE diagnosis of hard-to-identify bacterial infections



The broader problem

Sepsis, Urinary Tract Infection, Meningitis

Delayed diagnosis ➔FATAL

GlimmerX Technology

- Track record of discovery directed at unmet needs
  - Already done it
  - Newly applying it
  - Will apply it to new, untapped, vast opportunities

PLOS | NEGLECTED TROPICAL DISEASES

A Protein-Conjugate Approach to Develop a Monoclonal Antibody-Based Antigen Detection Test for the Diagnosis of Human Brucellosis



GlimmerDx Technology, newly applying it: LeptoX Proof-of-Principle

- New antigen discovery
- Uses novel immunochemical platform
- Develop ultrasensitive biosensors
- **Bottom line: we identify novel targets; from there, we make new diagnostics**

Previous work



Our novel IP



LeptoX: Initial focus; GlimmerX expanded scope

Scalable glycoconjugate platform with potential to capture **not only** HUMAN and ANIMAL segments for leptospirosis (LeptoX) but **will be applied** to vast new markets → **SEPSIS, UTI, MENINGITIS, ANTIBIOTIC RESISTANT BACTERIA (GlimmerX)**



Our Offering vs. Competition

Company	Diagnostic Method	Processing Time	Breadth of Diseases	Reliable Results	Affordable	Easy to Do
GlimmerX/ LeptoX	Antigen detection	15 minutes	✓	✓	✓	✓
ARUP	Molecular diagnosis (home-brewed)	~1-5 days	✗	?	✗	✗
PanBio, MRL Dx, Linnodee	Antibody detection (ELISA, latex agglutination, hemagglutination)	1-6 weeks	✗	✗	✓	✓
Hospital labs	Culture	2-3 months	✗	✗	✓	✗

Blavatnik Funds will enable GlimmerX

YEAR 1

- **Pilot $100,000**
  - Lepto: diagnostics prototypes
    ELISA; POC device
  - Pilot testing in animals
- **Full $300,000**

  Above plus
  - UTI , drug-resistant bacteria: diagnostics prototypes
  - *In vitro* testing
  - Pilot animal testing

YEAR 2 – 3

- **New**, nondilutive funding; early stage investment
- Create SOPs/protocols to enable pilot cGMP Diagnostic device/platforms scale up
  - For clinical testing in endemic sites
  - Licensing partners for manufacture/distribution

YEAR 4 – 5

- Early stage investment
- cGMP production
- Preclinical testing begins
- Veterinary trial testing
- Prepare for IND/Phase I human clinical trials

Thank You!

GlimmerX

Questions?

Contact

Joe Vinetz, M.D.
joseph.vinetz@yale.edu
(858) 945-7550

Carla Devillers, M.B.A.
carladevillers@gmail.com
(917) 545-7262